Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00001381 · ClinicalTrials.gov registry record · Phase 1

A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder

A Phase 1 study, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 1
Development phase
18
Enrollment target

NCT00001381: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).

NCT00001381 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 18 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00001381, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 1
Development phase
18 participants
Enrollment target

Study Summary

Patients with superficial transitional cell carcinoma of the bladder will be treated with intravesical suramin in a phase I dose escalating study. The toxicity of suramin administered in this fashion will be evaluated.

Interventions

  • DRUG suramin

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 1994-03
Est. Completion 2000-12
Phase Phase 1
National Cancer Institute (NCI)

3,257 total trials

What the finished NCT00001381 record still lists

NCT00001381 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower).

The record links to 0 conditions, and to 1 intervention - of which suramin is the first listed.

NCT00001381 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00001381 about?

NCT00001381 is a clinical study titled "A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder". Patients with superficial transitional cell carcinoma of the bladder will be treated with intravesical suramin in a phase I dose escalating study. The toxicity of suramin administered in this fashion will be evaluated.

What is the current status of trial NCT00001381?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 1994-03. Estimated completion is 2000-12.

What interventions are being tested in trial NCT00001381?

The interventions under investigation include: suramin (DRUG).

Who is sponsoring clinical trial NCT00001381?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00001381's enrollment target sits among peer trials

18 1720th of 2000 higher than 216 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01245179 · 18 participants · Phase 1

    Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease

  • NCT01999361 · 18 participants · NA

    Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

  • NCT02359825 · 18 participants · Phase 1

    Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function

  • NCT02870244 · 18 participants · Phase 1

    Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00001381, the US trial registry maintained by the National Library of Medicine. NCT00001381 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.